Clinical Trials
34 trialsNCT00936390 2026-03-06
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT03009981 2025-12-18
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance Foundation Trials, LLC.
Phase 3 Completed
NCT05605964 2025-08-17
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT05440383 2025-03-14
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
Kissei Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT00541047 2023-11-13
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
University College, London
Phase 3 Completed
NCT02941926 2023-10-24
COMPLEEMENT-1
Novartis
Phase 3 Completed
NCT04914195 2023-08-01
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
Bharat Serums and Vaccines Limited
Phase 3 Completed
NCT00005044 2022-06-15
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT03085095 2022-01-18
HERO
Myovant Sciences GmbH
Phase 3 Completed
NCT00116220 2022-01-06
Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer
Dana-Farber Cancer Institute
Phase 3 Completed
NCT00003653 2021-06-23
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00002633 2020-04-03
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT02085252 2019-06-28
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Takeda
Phase 3 Completed
NCT02655237 2019-03-22
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
Takeda
Phase 3 Completed
NCT00002597 2018-06-14
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00004635 2018-05-22
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT02980965 2017-11-13
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
Fudan University
Phase 3 Completed
NCT00193856 2017-10-12
RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
Trans Tasman Radiation Oncology Group
Phase 3 Completed
NCT00380406 2017-04-05
PROOF
Ottawa Hospital Research Institute
Phase 3 Completed
NCT01415960 2017-03-03
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
GP-Pharm
Phase 3 Completed
NCT00928434 2016-12-13
A Study of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT01011751 2015-07-30
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
Takeda
Phase 3 Completed
NCT00378690 2014-06-04
ICELAND
Astellas Pharma Inc
Phase 3 Completed
NCT00002580 2013-11-06
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002582 2013-08-02
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00451958 2013-03-21
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
Ferring Pharmaceuticals
Phase 3 Completed
NCT00295750 2012-12-19
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT00283062 2012-01-26
Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
Sanofi
Phase 3 Completed
NCT00626431 2011-07-19
A Study of Leuprolide to Treat Prostate Cancer
Abbott
Phase 3 Completed
NCT00002881 2010-11-09
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00598312 2010-09-08
Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer
Oakwood Laboratories, LLC
Phase 3 Completed
NCT00076531 2008-01-28
Clinical Trial for Prostate Cancer
Oakwood Laboratories, LLC
Phase 3 Completed
NCT00128531 2007-11-14
Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer
GP-Pharm
Phase 3 Completed